Načítá se...
Baracle(®) vs Baraclude(®) for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety
BACKGROUND AND OBJECTIVE: Entecavir (ETV) is a standard of care for chronic hepatitis B (CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle(®)) was found to have a pharmacokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude(®)). The present study was conducted to e...
Uloženo v:
Vydáno v: | Drug Des Devel Ther |
---|---|
Hlavní autoři: | , , , , , , , , , |
Médium: | Artigo |
Jazyk: | Inglês |
Vydáno: |
Dove Medical Press
2017
|
Témata: | |
On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5673034/ https://ncbi.nlm.nih.gov/pubmed/29184389 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S149199 |
Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|